Clinical Scorecard: Lonza to Acquire Five US CDMO Sites from Merck KGaA
At a Glance
Category
Detail
Condition
Corporate acquisition of five US CDMO sites and associated businesses
Key Mechanisms
The transaction transfers five US sites and associated businesses to Lonza, covering bioconjugation, high-potency payload-linkers used in antibody-drug conjugates, viral vectors, lipid nanoparticles, liposomes, and PEGylated proteins.
Target Population
Pharmaceutical, biotechnology, and CDMO customers using the acquired services
Care Setting
US CDMO operations supporting products from clinical development through commercial manufacturing
Key Highlights
Lonza agreed to acquire five US CDMO sites from Merck KGaA; the transaction is expected to close in mid-2027, subject to regulatory approval and other customary conditions.
Approximately 1,100 employees will transfer to Lonza, and its number of US manufacturing sites will increase from four to nine.
The sites provide services across bioconjugation, high-potency payload-linkers used in antibody-drug conjugates, viral vectors, lipid nanoparticles, liposomes, and PEGylated proteins.
The acquired businesses are expected to generate approximately CHF250 million in sales in 2028; their core EBITDA margin is expected to be initially below Lonza’s group average.
Merck KGaA’s BioReliance Contract Testing Services business is excluded and will remain in its Life Science portfolio.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Not applicable; the article concerns a corporate acquisition of CDMO sites, not patient treatment.
No prescribing or treatment recommendations are reported. The acquired operations support development and manufacturing of complex modalities, including viral vectors and antibody-drug-conjugate components.
